(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) Wall Street was higher at the open on Monday and the Nasdaq inched closer to its record intraday high ahead of Apple's results after the close. The Dow Jones industrial average was up 0.34 percent at 18,141.57, the S&P 500 was up 0.25 percent at 2,123 and the Nasdaq Composite was up 23.32 points, or 0.46 percent, at 5,115.41.
** APPLE INC, $132.88, +2.00 pct
Brean Capital started the iPhone maker's stock with a "buy" rating and a target price of $160, ahead of the company's second-quarter results scheduled after markets close.
The stock was the second-most traded on the Nasdaq.
** MYLAN NV, $73.22, -3.73 pct
** TEVA PHARMACEUTICAL INDUSTRIES LTD, $63.03, -2.14 pct
** PERRIGO COMPANY PLC, $193.64, +0.39 pct
Mylan rejected the Israel-based company's unsolicited $40 billion takeover offer, saying it "grossly undervalues" the company. It also said it was committed on its offer for Perrigo. B.Riley, meanwhile, downgraded the Dublin-based drug company to "neutral" from "buy".
Mylan shares were among the 10 most traded on the Nasdaq.
** CELLADON CORP, $2.85, -79.17 pct
Data showed that the gene therapy developer's sole therapy in development, Mydicar, failed a key trial in patients with heart failure, leaving company "surprised and very disappointed."
The stock was the top percentage loser on the Nasdaq and the third-most traded.
** CAN-FITE BIOPHARMA LTD, $3.15, +46.51 pct
The Israeli drug developer reported promising analysis of late-stage trial data on an experimental psoriasis drug, codenamed CF101.
** TRUECAR INC, $16.35, +4.67 pct
Goldman Sachs upgraded the online car-shopping service provider's stock to "buy" from "neutral", citing faster traffic growth, ramped up advertising spend and higher U.S. new car sales.
** AKORN INC, $44.05, -20.26 pct
The generic drug maker said it may not be able to file its first-quarter results on time and would restate statements for the second, third and fourth quarters and the full year of 2014 due to some errors identified.
Piper Jaffray cut the stock to "neutral" and lowered its price target to $53 from $66, saying the restatement raised "credibility questions". JPM cuts its price target to $58 from $61.
The stock was the second-biggest percentage loser on the Nasdaq and were among the most traded.
** PERFECT WORLD CO LTD, $19.2, +3.67 pct
The Chinese game developer said on Sunday that it would be taken private by Perfect Peony Holding Co Ltd at a premium of 28.2 percent to Perfect World's Dec. 31 closing price of $15.76 per American Depositary Share.
** APPLIED MATERIALS INC, $20.325, -6.77 pct
Applied Materials Inc and Tokyo Electron Ltd said they have given up plans to merge in a deal that would have been worth more than $10 billion, citing problems in getting approval from U.S. antitrust regulators.
The stock was the most traded on the Nasdaq.
** 3D SYSTEMS, $26.43, -2.94 pct
** STRATASYS, $50.775, -0.98 pct
At least two brokerages downgraded and four cut their price targets on 3D Systems' stock after the 3D-printer maker estimated first-quarter revenue and profit below average forecasts on Friday.
** RESTAURANT BRANDS INTERNATIONAL INC, $42.4, +2.00 pct
The company formed out of Burger King's takeover of Canadian coffee and doughnut chain Tim Hortons last year, said its loss narrowed in the first quarter compared with the fourth quarter of 2014.
** LSB INDUSTRIES INC, $46, +2.98 pct
The chemical and climate control products maker would split chemicals and climate control units after pressure from activist shareholder Starboard Value LP.
** IGATE CORP, $47.415, +3.41 pct
French IT services company Cap Gemini SA said it planned to buy United States-based IGATE for $4 billion to make North America, its biggest market, and is raising its sales forecast for 2015 after a solid first quarter.
** MARVEL TECHNOLOGY GROUP LTD, $14.11, -1.36 pct
The chipmaker cut its first-quarter revenue forecast to $710 million-$740 million from $810 million-$830 million, citing lower-than-expected demand from personal computer and storage markets and from emerging markets.
** DEUTSCHE BANK, $32.6, -4.85 pct
The German bank's biggest strategic overhaul under co-chief executives Anshu Jain and Juergen Fitschen got a thumbs down from investors on Monday who judged it too little too late. (Compiled by Avik Das in Bengaluru; Editing by Joyjeet Das)